HOSPITAL MASSACHUSETTS GENERAL HOSPITAL AFFILIATE		(Patient Stic	ker)
PHYSICIAN ORD PROLAS			
CDH 208-227 – Approved -			
Patient:	DOB:	Gender:	
Patient Phone #:	Height:	Weight:	
Diagnosis:	ICD-10 Code:		
Treatment Start Date:			
Provider Facility Name:	Provider Facility Ac	dress:	
Ordering Provider:	Date:		
Signature:			
ledications	Inte	Defer Listi	Durotion
 alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient8 minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual do NOT Refrigerate. Use within 3 hours of reconstitution 	kg On s ss), the infusion should be stopped unt k#39;s physician. Monitor vital signs (h n patients at risk for fluid overload. Sol lose administered will be within +/- 10%	il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a	infusion, 20 Infter mixing. Infuse
alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient8 minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual do NOT Refrigerate. Use within 3 hours of reconstitution	kg On s ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol lose administered will be within +/- 10%	CE il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins	1 treatment sion may then be infusion, 20 after mixing. Infuse stitution policy. DO
alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient& minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual do NOT Refrigerate. Use within 3 hours of reconstitution	kg On s ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol lose administered will be within +/- 10%	CE il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until	1 treatment sion may then be infusion, 20 lifter mixing. Infuse
alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient& minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual d NOT Refrigerate. Use within 3 hours of reconstitution abs	kg On s ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol ose administered will be within +/- 10% Inte On	Ce il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until Ce	1 treatment sion may then be infusion, 20 ifter mixing. Infuse stitution policy. DO
 alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient& minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual du NOT Refrigerate. Use within 3 hours of reconstitution abs CBC 	kg On s ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol ose administered will be within +/- 10% Inte On	Ce il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until Ce MCH, MCHC, PLT.	1 treatment sion may then be infusion, 20 ifter mixing. Infuse stitution policy. DO
 alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient8 minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual do NOT Refrigerate. Use within 3 hours of reconstitution abs CBC Routine, Once, Starting S For 1 Occurrences, CBC in BUN 	kg On s s sss), the infusion should be stopped unt k#39;s physician. Monitor vital signs (h n patients at risk for fluid overload. Sol ose administered will be within +/- 10%. ose administered will be within +/- 10%. Interview On octuates: HCT, HGB, WBC, RBC, MCV,	Ce il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until Ce MCH, MCHC, PLT. Ce	1 treatment sion may then be infusion, 20 ifter mixing. Infuse stitution policy. DO Duration 1 treatment
 alpha-1 proteinase inhibitor IVPB 60 mg/ 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient8 minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual do NOT Refrigerate. Use within 3 hours of reconstitution abs CBC Routine, Once, Starting S For 1 Occurrences, CBC in BUN Routine, Once, Starting S For 1 Occurrences Creatinine, random urine 	kg On s Ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol ose administered will be within +/- 10%. Inte Intel On hcludes: HCT, HGB, WBC, RBC, MCV, On On On on On on On hcludes: HCT, HGB, WBC, RBC, MCV, On On On NH Urinalysis sediments are performed	Ce il symptoms subside. The infus eart rate, blood pressure) pre-i ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until Ce MCH, MCHC, PLT. Ce Ce Ce prmed on all urines that have p	1 treatment sion may then be infusion, 20 ifter mixing. Infuse stitution policy. DO Duration 1 treatment 1 treatment 1 treatment 1 treatment 1 treatment
 60 mg/kg, Intravenous, Once, Starting H, For 1 Doses If adverse events occur (light-headedness or dizzines resumed at a slower rate after consulting the patient& minutes into infusion and post-infusion. Use caution in over a maximum rate of 0.08 mL/kg/min The actual du NOT Refrigerate. Use within 3 hours of reconstitution abs CBC Routine, Once, Starting S For 1 Occurrences, CBC in BUN Routine, Once, Starting S For 1 Occurrences Creatinine, random urine Routine, Once, Starting S For 1 Occurrences Urinalysis Routine, Once, Starting S For 1 Occurrences, *Excep 	kg On s Ss), the infusion should be stopped unt 's physician. Monitor vital signs (h n patients at risk for fluid overload. Sol ose administered will be within +/- 10%. Inte Intel On hcludes: HCT, HGB, WBC, RBC, MCV, On On On on On on On hcludes: HCT, HGB, WBC, RBC, MCV, On On On NH Urinalysis sediments are performed	Ce il symptoms subside. The infus eart rate, blood pressure) pre-i- ution is only stable for 3 hour a 6 of the ordered dose or per ins erval Defer Until Ce MCH, MCHC, PLT. Ce Ce Ce prmed on all urines that have p lered separately.	1 treatment sion may then be infusion, 20 ifter mixing. Infuse stitution policy. DO Duration 1 treatment 1 treatment 1 treatment 1 treatment 1 treatment

\sim	COOLEY DICKINSON
	HOSPITAL
V	MASSACHUSETTS GENERAL HOSPITAL AFFILIATE

	PHYSICIAN ORDER SET :				
	PROLASTIN				
	CDH 208-227 – Approved - Page 2 of 3				
DS ((continued)				
_	DTT	Inter		Defer Until	Duration
	PTT Routine, Once, Starting S For 1 Occurrences	Once	e		1 treatment
	Comprehensive metabolic panel(BWH , BWF , DFCI , NWH ,	Once	е		1 treatment
	MEEI, NSMC, SCC, SRH, SHC, NCH, MVH) Routine, Once, Starting S For 1 Occurrences, consists of the following tests: Na, K, Cl Alkaline Phosphatase, Total Bilirubin, Total Protein, ALT, and AST	, CO2,	BUN, Glu	icose, Creatinine, C	alcium, Albumin,
	PT-INR	Once	e		1 treatment
_	Routine, Once, Starting S For 1 Occurrences	000			1 tractment
	Glucose Routine, Once, Starting S For 1 Occurrences	Once	e		1 treatment
	CPK (creatine kinase)	Once	е		1 treatment
	Routine, Once, Starting S For 1 Occurrences				
	Alanine aminotransferase (ALT) Routine, Once, Starting S For 1 Occurrences	Once	e		1 treatment
	Aspartate aminotransferase (AST)	Once	e		1 treatment
	Routine, Once, Starting S For 1 Occurrences		-		
ho	ter management				
inc	ter management	Inter	val	Defer Until	Duration
	Line Access	PRN		Deler ontin	Until discont
	Routine, Once, Starting S For 1 Occurrences, As needed. Starting when released. Unt	•			
_	Insert peripheral IV, or access peripheral, or central venous access device, to provide				
	alteplase (CATHFLO) 1 mg/mL injection 2 mg 2 mg, Intracatheter, As needed, line care, For central venous access device requiring of	PRN clearan		nister per institution	Until discont' al quidelines. Mav
	repeat once per lumen., Starting S			F	
	lidocaine-prilocaine (EMLA) cream Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion or port and			3	Until discont
	heparin 100 units/mL flush 5 mL	PRN		,	Until discont
	5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting				
	heparin 10 units/mL flush 3 mL	PRN			Until discont
_	3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting	-			Lintil diagont
	heparin 10 units/mL flush 5 mL 5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting	PRN 1 S			Until discont
	heparin 1000 units/mL flush 2 mL	PRN			Until discont
	2 mL, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per instituti FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHER				THDRAWN
	sodium chloride (NS) 0.9 % syringe flush 3 mL	PRN	-		Until discont
	3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Starting	-			
	sodium chloride (NS) 0.9 % syringe flush 10 mL 10 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Startin	PRN ng S	I		Until discont
	sodium chloride (NS) 0.9 % syringe flush 20 mL 20 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Startin	PRN	1		Until discont
	sodium chloride 0.9% infusion	PRN	1		Until discont
	20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to prov			tarting S	
	D5W infusion	PRN			Until discont
	20 ml /br. Intravenous, Continuous PRN, other (free text field). Keep vein open to prov	ido tros	atmont S	tarting S	

20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provide treatment, Starting S

25	COOLEY DICKINSON HOSPITAL massachusetts general hospital affiliate		(Patient Stic	ker)
	PHYSICIAN ORDER SET :			
	PROLASTIN			
	CDH 208-227 – Approved - Page 3 of 3			
nerç	gency Medications			
	Provider and Nurse Communication Routine, Until discontinued, Starting S, Treatment of SEVERE reaction (ANAPHYLA) distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine administer oxygen as needed, monitor vital signs and proceed with administering adj	e FIRST. Notify p	provider and emerge	ncy personnel,
	indicated. EPINEPHrine injection 0.3 mg 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. M For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is e			Until discont'd
	sodium chloride 0.9% bolus 1,000 mL 1,000 mL, Intravenous, Once as needed, other (free text field), For hypotension, Star	PRN		Until discont'd
	Oxygen Therapy - Non-Rebreather Routine	PRN		Until discont'd
	Select a Mode of Therapy: Non-Rebreather Tryptase	PRN		Until discont'd
/per	STAT, Once, Starting S For 1 Occurrences Collect for mild-moderate, or SEVERE reaction sensitivity			
	Sensitivity			
		Interval	Defer Until	Duration
	Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-modera and emergency personnel, administer oxygen as needed, monitor vital signs and pro indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section.	PRN te infusion react	ion: Stop the infusior	Until discont'd n, notify provider
	Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-modera and emergency personnel, administer oxygen as needed, monitor vital signs and pro indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg	PRN te infusion react ceed with admin PRN	ion: Stop the infusior istering medications	Until discont'd n, notify provider as clinically Until discont'd
	Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-modera and emergency personnel, administer oxygen as needed, monitor vital signs and pro indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, sho	PRN te infusion react ceed with admin PRN ortness of breath	ion: Stop the infusior istering medications	Until discont'd n, notify provider as clinically Until discont'd oses
	Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-modera and emergency personnel, administer oxygen as needed, monitor vital signs and pro indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg	PRN te infusion react ceed with admin PRN	ion: Stop the infusior istering medications	Until discont'd n, notify provider as clinically Until discont'd oses
	 Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderal and emergency personnel, administer oxygen as needed, monitor vital signs and proindicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, sho acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has 	PRN te infusion react ceed with admin PRN ortness of breath PRN PRN	ion: Stop the infusior istering medications n, Starting S, For 1 D	Until discont'd n, notify provider as clinically Until discont'd oses Until discont'd Until discont'd
	 Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderal and emergency personnel, administer oxygen as needed, monitor vital signs and proindicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, shore the acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has Starting S famotidine (PEPCID) injection 20 mg 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild 	PRN te infusion react ceed with admin PRN ortness of breath PRN PRN as continued reac	ion: Stop the infusior istering medications n, Starting S, For 1 D ction, administer add	Until discont'd as clinically Until discont'd oses Until discont'd Until discont'd Ititional 25 mg, Until discont'd
	 Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderal and emergency personnel, administer oxygen as needed, monitor vital signs and proindicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, she acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has Starting S 	PRN te infusion react ceed with admin PRN ortness of breath PRN as continued reac PRN d-moderate, or S PRN	ion: Stop the infusior istering medications n, Starting S, For 1 D ction, administer add SEVERE reaction Ho	Until discont'd as clinically Until discont'd oses Until discont'd Until discont'd Until discont'd Id if: given as Until discont'd
	 Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderat and emergency personnel, administer oxygen as needed, monitor vital signs and proindicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, she acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has Starting S famotidine (PEPCID) injection 20 mg 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mild premed, Starting S, For 1 Doses cetirizine (ZyrTEC) tablet 10-20 mg 10-20 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or S 	PRN te infusion react ceed with admin PRN ortness of breath PRN as continued reac PRN d-moderate, or S PRN SEVERE reaction PRN	ion: Stop the infusior istering medications n, Starting S, For 1 D ction, administer add SEVERE reaction Ho n, Starting S, For 1 D	Until discont'd as clinically Until discont'd oses Until discont'd Until discont'd Until discont'd Id if: given as Until discont'd oses Until discont'd
	 Provider and Nurse Communication Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderate and emergency personnel, administer oxygen as needed, monitor vital signs and proindicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. albuterol (ACCUNEB) nebulizer solution 2.5 mg 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing, she acetaminophen (TYLENOL) tablet 975 mg 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses diphenhydrAMINE (BENADRYL) injection 25 mg 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patient has Starting S famotidine (PEPCID) injection 20 mg 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for mill premed, Starting S, For 1 Doses cetirizine (ZyrTEC) tablet 10-20 mg 10-20 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SHOLD IF giving fexofenadine. fexofenadine (ALLEGRA) tablet 90-180 mg 90-180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or SHOLD IF giving fexofenadine. 	PRN te infusion react ceed with admin PRN ortness of breath PRN as continued reac PRN d-moderate, or S PRN SEVERE reaction PRN SEVERE reaction	ion: Stop the infusior istering medications n, Starting S, For 1 D ction, administer add SEVERE reaction Ho n, Starting S, For 1 D on, Starting S, For 1 D	Until discont'd n, notify provider as clinically Until discont'd oses Until discont'd litional 25 mg, Until discont'd lid if: given as Until discont'd Doses Until discont'd Doses

version 8/25/2017